Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring

Sophie Susen 1,2*, Charles Ambroise Tacquard 3, Alexandre Godon 4, Alexandre Mansour 5, Delphine Garrigue 1, Philippe Nguyen 6, Anne Godier 7, Sophie Testa 8, Jerrold H. Levy 9, Pierre Albaladejo 4, Yves Gruel 10* on behalf of GIHP and GFHT 11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48

Abstract

COVID-19 is an infection induced by the SARS-CoV-2 coronavirus, and severe forms can lead to acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) management. Severe forms are associated with coagulation changes, mainly characterized by an increase in D-dimer and fibrinogen levels, with a higher risk of thrombosis, particularly pulmonary embolism. The impact of obesity in severe COVID-19 has also been highlighted. In this context, standard doses of low molecular weight heparin (LMWH) may be inadequate in ICU patients, with obesity, major inflammation, and hypercoagulability. We therefore urgently developed proposals on the prevention of thromboembolism and monitoring of hemostasis in hospitalized patients with COVID-19.

Four levels of thromboembolic risk were defined according to the severity of COVID-19 reflected by oxygen requirement and treatment, the body mass index, and other risk factors. Monitoring of hemostasis (including fibrinogen and D-dimer levels) every 48 h is proposed. Standard doses of LMWH (e.g., enoxaparin 4000 IU/24 h SC) are proposed in case of intermediate thrombotic risk (BMI < 30 kg/m², no other risk factors and no ARDS). In all obese patients (high thrombotic risk), adjusted prophylaxis with intermediate doses of LMWH (e.g., enoxaparin 4000 IU/12 h SC or 6000 IU/12 h SC if weight > 120 kg), or unfractionated heparin (UFH) if renal insufficiency (200 IU/kg/24 h, IV), is proposed. The thrombotic risk was defined as very high in obese patients with ARDS and added risk factors for thromboembolism, and also in case of extracorporeal membrane oxygenation (ECMO), unexplained catheter thrombosis, dialysis filter thrombosis, or marked inflammatory syndrome and/or hypercoagulability (e.g., fibrinogen > 8 g/l and/or D-dimers > 3 μg/ml). In ICU patients, it is sometimes difficult to confirm a diagnosis of thrombosis, and curative anticoagulant treatment may also be discussed on a probabilistic basis. In all these situations, therapeutic doses of LMWH, or UFH in case of renal insufficiency with monitoring of anti-Xa activity, are proposed.

(Continued on next page)

* Correspondence: Sophie.SUSEN@CHRU-LILLE.FR; yves.gruel@univ-tours.fr

Proposals from the French Working Group on Perioperative Hemostasis (GIHP) and the French Study Group on Thrombosis and Hemostasis (GFHT), in collaboration with the French Society for Anesthesia and Intensive Care (SFAR)

1Department of Hematology and Transfusion, Lille University Hospital, Lille, France

10Department of Hematology-Hemostasis, Tours University Hospital, CHRU Tours, Tours, France

Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
COVID-19 is an infection induced by the SARS-CoV-2 coronavirus affecting mostly adults. This viral disease is mild in many patients but is characterized in symptomatric forms by an atypical interstitial inflammatory lung disease [1]. In addition, severe forms are associated with an extreme inflammatory reaction related to a “cytokine storm,” with lung involvement that can lead to acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) management.

In critically ill patients, especially those with hypoxemia, coagulation changes reflecting inflammation are generally observed, with increased D-dimer and fibrinogen levels [2] and, more rarely, a consumptive coagulopathy associated with a poor prognosis [2].

The pathophysiology of SARS-Cov2 infection is still poorly defined, but major inflammation and hypoxemia associated with a prothrombotic state are significant features of severe forms. Chinese, Italian, North American, and French cohorts have consistently reported that severe forms affect more often elderly patients with comorbidities (hypertension, diabetes, cardiovascular or pulmonary pathology), with high mortality in those requiring ICU admission [3–6].

More recently, the impact of obesity, often associated with other comorbidities, has been highlighted in severe forms of COVID-19 [7]. A French study has also confirmed that almost half of the patients admitted to ICU are obese (with BMI > 30 kg/m²) and require mechanical ventilation more often [8].

A Chinese study reported frequent venous thrombotic episodes in severe COVID-19 [9], and survival was improved with heparin thromboprophylaxis [2]. In another report, venous thromboembolic events occurred in 27% of 187 Dutch patients with COVID-19 hospitalized in the ICU [10]. Further, reports from Italy, France, and Switzerland have observed frequent venous thromboembolic complications in COVID-19 with a risk that appears particularly high in patients requiring ICU admission and/or with obesity, and frequent clotting of indwelling catheters, dialysis filters, ECMO oxygenators, and arterial thrombotic events including acute limb ischemia or stroke. In addition, pulmonary embolism has recently been identified as the most common thrombotic event occurring despite thromboprophylaxis [11, 12].

However, no study has formally documented an increased thrombotic risk in COVID-19 compared to other severe infections, nor demonstrated that this risk was associated with a poor prognosis. Nevertheless, some pathophysiological features (major inflammation in particular) and the populations affected by this pathology (with comorbidities, particularly obesity) lead to further debates on the specific thromboprophylaxis treatment modalities for COVID-19.

Although low molecular weight heparin (LMWH) is the therapy of choice in patients with severe infections, current dosing strategies [13, 14] may be inadequate in patients with increased inflammatory responses and obesity and critically ill in the ICU. In addition, we are confronted with a highly challenging medical situation, with a large influx of severe patients in ICUs and in whom it is much more difficult to confirm a diagnosis of thrombosis, which explains why the implementation of curative anticoagulant treatment can sometimes be discussed on a probabilistic basis.

In this context, given the paucity of available data, the Groupe d’intérêt en Hémostase Périopératoire (GIHP) and the Groupe Français d’études sur l’Hémostase et la Thrombose (GFHT) have developed a guidance document on the prevention of thrombosis and monitoring of hemostasis in hospitalized patients with COVID-19 in order to provide support for clinical management.

These proposals, developed by a large group of reviewers, members of the GIHP and the GFHT, are organized into 4 objectives and will be modified according to the evolution of our knowledge on COVID-19.

Practical proposals
Objective no. 1: To define the risk of thrombosis in patients with COVID-19
Proposal no. 1
All COVID-19 patients should be screened for additional thromboembolic risk factors, especially active cancer (treatment within the last 6 months) and recent personal history (< 1 year) of thromboembolic events.
Other risk factors may be considered (age > 70 years, prolonged bed rest, postpartum, combined oral contraception).

Proposal no. 2
To define the thrombotic risk level according to the following:
- The severity of COVID-19 according to the requirement of supplemental oxygen (O₂) therapy, high-flow...
nasal oxygen therapy, positive airway pressure support, or mechanical ventilation.
- The body mass index (BMI)

Then, 4 different levels of thromboembolic risk can be determined: low, intermediate, high, and very high (Table 1).

**Objective no. 2: Monitor the hemostasis**

**Proposal no. 3**

It is suggested that the following hemostasis variables be monitored at least every 48 h: platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, and D-dimer levels.

**Proposal no. 4**

In severe cases, in the event of clinical worsening, thrombocytopenia and/or a decrease in fibrinogen concentration, it is proposed that the concentration of fibrin monomers (if assay available), factors II and V, and anti-thrombin levels should also be measured for the diagnosis of disseminated intravascular coagulation (DIC).

**Proposal no. 5**

It is proposed that the presence of antiphospholipid antibodies should be investigated for iterative thrombosis under heparin therapy at effective doses.

**Objective no. 3: Prescribe anticoagulant therapy**

**Proposal no. 6**

In all hospitalized patients, it is proposed to switch from oral anticoagulant therapy, vitamin K antagonist or direct oral anticoagulant (risk of instability and drug interactions), to curative heparin therapy.

**Proposal no. 7**

In case of intermediate thrombotic risk (Fig. 1), it is proposed to prescribe prophylaxis with a LMWH at standard doses, e.g., enoxaparin 4000 IU/24 h SC, tinzaparin 3500 IU/24 h SC, or dalteparin 5000 IU/24 h SC. Fondaparinux 2.5 mg/24 h SC is an alternative if creatinine clearance (Clcr) is greater than 50 ml/min. In the presence of severe renal failure, an alternative to SC unfractionated heparin (UFH) can be proposed: enoxaparin 2000 IU/24 h SC for a Clcr between 15 and 30 ml/min or tinzaparin 3500 IU/24 h SC for a Clcr between 20 and 30 ml/min.

**Proposal no. 8**

In patients treated with LMWH with standard prophylactic doses, it is recommended NOT to monitor anti-Xa activity.

**Proposal no. 9**

In case of high thrombotic risk, it is proposed to prescribe an adjusted prophylaxis with intermediate doses of LMWH: enoxaparin 4000 IU/12 h SC or 6000 IU/12 h SC if weight > 120 kg. In case of renal insufficiency (Clcr < 30 ml/min), it is proposed to prescribe UFH at an initial dose of 200 IU/kg/24 h, IV.

**Proposal no. 10**

In patients treated with LMWH doses higher than the standard prophylactic regimen, it is proposed to check anti-Xa activity 4 h after the 3rd injection, then regularly in case of renal insufficiency, to monitor for levels (variable threshold value according to LMWH) due to the potential increased risk of bleeding.

**Table 1**

| BMI category | Treatment recommendations |
|-------------|--------------------------|
| BMI < 30 kg/m² | No oxygen therapy: LMWH with standard prophylactic dose or fondaparinux (e.g., enoxaparin 4000 IU/24 h SC, or 2000 IU/24 h SC if Clcr between 15 and 30 ml/min); tinzaparin 3500 IU/24 h SC if Clcr > 20 ml/min; dalteparin 5000 IU/24 h SC if Clcr > 30 ml/min. Fondaparinux 2.5 mg/24 h if Clcr > 50 ml/min. | Oxygen therapy: High flow nasal oxygen therapy or mechanical ventilation. Monitoring of anti-Xa activity: - LMWH: avoid overdose (maintain anti-Xa < 1.2 IU/ml for enoxaparin) - UFH: target 0.3–0.5 IU/ml (+ platelet count every 48 hours). |
| BMI 30–35 kg/m² | Without other thrombotic risk factor* | enoxaparin 4000 IU/12 h SC if weight > 120 kg UFH: 200 IU/kg/24 h, if Clcr < 30 ml/min. |
| BMI ≥ 35 kg/m² with thrombotic risk factor* | LMWH at curative dose e.g., enoxaparin 100 IU/kg/12 h SC (actual weight), without exceeding 10,000 IU/12 h. UFH 500 IU/kg/24 h if Clcr < 30 ml/min. Re-evaluate the dose in case of multiorgan failure or consumption coagulopathy. | Monitoring of anti-Xa activity: - LMWH: avoid overdose (maintain anti-Xa < 1.2 IU/ml for enoxaparin) - UFH: target 0.5–0.7 IU/ml (+ platelet count every 48 hours). |

*Thromboembolic Risk Factors: active cancer; recent personal history of thrombosis... Clcr: Creatinine clearance; LMWH: low molecular weight heparin; UFH: unfractionated heparin

**Fig. 1** Prevention and treatment of thrombosis in hospitalized patients with COVID-19
Proposal no. 11
In case of very high thrombotic risk, it is proposed to pre-
scribe therapeutic doses of LMWH, e.g., enoxaparin, 100
IU/kg/12 h SC, or in case of severe renal insufficiency of
UFH, 500 IU/kg/24 h, IV after a bolus of 5000 IU, and
with dosage adjustment according to anti-Xa activity.

Proposal no. 12
In obese patients (BMI > 30 kg/m²) with a high or very
high thrombotic risk, the following heparin doses are
proposed:

a. Enoxaparin 4000 IU/12 h or 6000 IU/12 h if
weight > 120 kg in high-risk patients
b. Enoxaparin 100 IU/kg (actual weight)/12 h SC not
to exceed 10,000 IU/12 h or UFH 500 IU/kg/24 h in
very high-risk patients with additional thrombotic
risk factor and high-flow nasal O₂ therapy or artifi-
cial ventilation

Proposal no. 13
In all patients treated with UFH, it is proposed to moni-
tor the anti-Xa activity at least every 48 h and after each
dose modification, to be maintained, if the risk of bleed-
ing is controlled, between 0.3 and 0.5 IU/ml during rein-
forced prophylactic treatment (starting dose 200 IU/kg/
24 h, IV) and between 0.5 and 0.7 IU/ml during ther-
apeutic treatment (starting dose 500 IU/kg/24 h, IV, after
an initial IV bolus of 5000 IU).

Proposal no. 14
The use of extracorporeal membrane oxygenation (ECMO)
exposes the patient to a very high risk of thrombosis. In this
setting, we propose therapeutic anticoagulation with UFH as
soon as ECMO is initiated (independently of the ECMO flow
rate), with a target anti-Xa level between 0.5 and 0.7 IU/ml.

Proposal no. 15
In case of an increased inflammatory syndrome (e.g., fi-
brinogen > 8 g/l or 800 mg/dl) and/or a rapid increase in
D-dimer concentration to > 3 μg/ml (3000 ng/ml), it is
suggested that the administration of therapeutic doses of
heparin be considered even in the absence of clinical
thrombosis, taking into account the risk of hemorrhage.

Proposal no. 16
For UFH, it is recommended that platelet count should
be monitored at least every 48 h. A decrease in the plate-
let count by more than 40% between the 4th and 14th
day of treatment requires a DIC assessment and a
screening for heparin-induced thrombocytopenia.

Proposal no. 17
In the event of multiorgan failure, or a consumptive co-
agulopathy with decrease in fibrinogen concentration,
platelet count, and factor V level, it is proposed that the
dosage of heparin therapy be reassessed, as these events
are associated with an increased risk of bleeding.

Proposal no. 18
It is proposed that the intensity and duration of thrombo-
prophylaxis be re-evaluated according to the severity of the
infection and the evolution of the resulting risk factors.

Objective no. 4: Apply additional measures for optimal
management of thrombotic risk

Proposal no. 19
Discontinuation of hormonal or hormone-related ther-
apy (estrogen-progestin contraception, hormone replace-
ment therapy, tamoxifen) is recommended in patients
with COVID-19 requiring thromboprophylaxis.

Proposal no. 20
It is proposed to implement a specific communication
pathway between the clinical units and the hemostasis
laboratory, for optimal transmission of biological results
(in particular, platelet count, fibrinogen, D-dimer, and
anti-Xa activity) for rapid adaptation of heparin therapy.

Proposal no. 21
It is suggested that pulmonary embolism be investigated
in any patient with sudden respiratory or hemodynamic
deterioration, especially in the case of right ventricular
dysfunction.

Proposal no. 22
A proximal vein compression ultrasonography with
Doppler of the common femoral and popliteal veins is
proposed in the event of any unexplained clinical wors-
ening, or in the case of a sudden increase in D-dimer
levels.

This examination may also be performed earlier in pa-
tients with a central venous catheter, especially in case
of dysfunction or obstruction.

Proposal no. 23
The insertion of a vena cava filter is not warranted in
these patients at low risk for bleeding.

Proposal no. 24
Intermittent pneumatic compression is an option to be
considered if available in patients at a high risk of
bleeding.
Discussion

With these practical proposals, we aimed to assist clinicians in the therapy and monitoring of anticoagulation to prevent thrombosis in hospitalized patients with COVID-19. As a result, we did not address the management of a consumptive coagulopathy, which can occur in severe patients, nor certain situations such as ambulatory patients, pregnancy, or patients with underlying diseases (e.g., sickle cell disease, congenital hemostatic defects), as well as the role of thrombolysis, antiplatelet drugs, and the management of arterial thrombotic events.

We first proposed defining the level of thrombotic risk according to the severity of the disease, i.e., the presence or absence of hypoxemia and BMI (Table 1). Other additional risk factors for thromboembolism such as recent thrombosis or active cancer must also be considered.

Antithrombotic prophylaxis is not required in case of low risk, but is necessary in all hospitalized and immobile patients, as for any severe acute infection [13, 14], with preference given to heparins. Interestingly, a specific beneficial effect of heparin on COVID-19 is also suggested, due to its pleiotropic actions (cytokine binding, inhibition of chemotaxis, leukocyte migration, and complement activation, sequestration of inflammatory proteins) [15].

In the less severe forms and if the BMI is < 30 kg/m² (intermediate risk), it is recommended, in accordance with the most recent guidelines [14], to prescribe fondaparinux or a LMWH at a standard dose (e.g., enoxaparin 4000 IU/24 h SC).

But in obese patients (BMI > 30 kg/m²), who present a higher thrombotic risk, we suggest increased doses of LMWH, in accordance with ESC proposals in other scenarios [16]. However, in the absence of data on the bleeding risk associated with higher doses of LMWH in the context of COVID-19, it is preferable not to initially exceed 10,000 IU/12 h of enoxaparin SC.

In ICU patients, the thrombotic risk is frequently high [17], especially in case of sepsis [18], and prophylaxis at usual doses may be ineffective, and more importantly in case of obesity [19]. Heparin therapy at therapeutic doses had been proposed during the H1N1 influenza, due to an increased thrombotic risk, particularly in patients with ARDS [20]. Moreover, the incidence of severe hemorrhagic accidents is rather low in COVID-19 patients [21, 22], whereas the thrombotic risk is high despite anticoagulation, as recently documented in 2 French cohorts [11, 12]. We therefore propose increased or even therapeutic doses (if additional thromboembolic risk factors are present) of LMWH or unfractionated heparin in COVID-19 patients hospitalized in ICUs. Thus, in obese patients with well-identified thromboembolic risk factors (active cancer or recent thrombosis in particular), therapeutic doses of LMWH adjusted according to actual weight [23] will be preferentially administered. Therapeutic dosing of heparin is also indicated in cases of thrombosis or during ECMO. However, it should also be considered in cases of a major inflammatory syndrome associated with severe pulmonary involvement, which often results in elevated fibrinogen and/or D-dimer concentrations, also indicating a severe prothrombotic state, regardless of BMI. The increase in D-dimer levels in COVID-19 is more pronounced in the most critically ill patients [24], with a concentration often greater than 3 μg/ml [2]. In addition, mortality was lower in patients whose D-dimer levels were above this threshold, when treated with heparin [25]. Therefore, these variables should be measured regularly, and a rapid increase in the level of D-dimers (outside of DIC) and/or fibrinogen should prompt to search for a thrombotic event and discuss the administration of therapeutic doses of heparin. In practice, an intensification of heparin treatment should be considered based on clinical and biological considerations of severity, but such a proposal is debated

**Table 1** Thrombotic risk levels in patients with COVID-19 according to BMI, requirement of O₂ or mechanical assistance, and other risk factors of thrombosis

| Low risk | Intermediate risk | High risk | Very high risk |
|----------|------------------|-----------|---------------|
| Non-hospitalized patient with BMI < 30 kg/m² and no added risk factors for thromboembolism (such as active cancer, recent history of thrombosis) | BMI < 30 kg/m², without the need for high-flow nasal oxygen therapy or mechanical ventilation, with or without added risk factors for thromboembolism | BMI < 30 kg/m², under high-flow nasal oxygen therapy or mechanical ventilation, with or without risk factors for thromboembolism | BMI > 30 kg/m² with added risk factors for thromboembolism, AND high-flow nasal oxygen therapy or mechanical ventilation |
| | | - BMI > 30 kg/m² without high-flow nasal oxygen therapy or mechanical ventilation, but with added risk factors for thromboembolism | - ECMO (venovenous or veno-arterial) |
| | | - BMI > 30 kg/m² with high-flow nasal oxygen therapy or mechanical ventilation, and without added risk factors for thromboembolism | - Unexplained catheter thrombosis |
| | | - Dialysis filter thrombosis | - Marked inflammatory syndrome and/or hypercoagulability (e.g., fibrinogen > 8 g/l (800 mg/dl) and/or D-dimers > 3 μg/ml or 3000 ng/ml) |
[26, 27], and clinical trials are mandatory. However in practice, when evaluation of thrombosis is not feasible, such as in critically ill ventilated patients, a probabilistic antithrombotic intensification should be considered when there is a high thrombotic risk.

Biologically, we propose to monitor prothrombin time, APTT, fibrinogen, and D-dimers at least every 48 h, combined in patients treated with UFH with monitoring of platelet count and anti-Xa activity (if curative doses and/or renal failure). This regular monitoring of hemostasis is crucial in all COVID-19 patients hospitalized with two main objectives as follows:

1. To evaluate the evolution of the disease using predictive markers of complications
2. To screen for heparin overdose, associated with a risk of bleeding, and heparin-induced thrombocytopenia (HIT) in UFH-treated patients

Anti-Xa activity, although not correlated with the occurrence of thrombosis or bleeding, especially in case of obesity [28], should be measured in patients receiving increased doses of LMWH, but is only intended to eliminate overdose (Fig. 1). Dosage adjustment to achieve a target value is therefore not recommended. In patients treated with UFH, dose adjustment based on anti-Xa activity is recommended [29]. Thus, we propose to maintain anti-Xa activity between 0.3 and 0.5 IU/ml during enhanced prophylactic treatment and between 0.5 and 0.7 IU/ml during therapeutic treatment. Platelet count should be monitored every 48 h between days 4 and 14 of treatment with UFH to detect HIT [30]. A relative heparin resistance has been described in COVID-19 [24], but infrequently. Rarely associated with a modest decrease in antithrombin level [24], it can be resolved in most cases by increasing heparin doses. Anti-thrombin supplementation, which can increase the risk of bleeding in ICU patients [31, 32], is not recommended [33], as well as argatroban, which should be reserved only for patients with HIT [30, 34].

In case of unexplained and/or atypical thrombosis, antiphospholipid antibodies can also be detected [35] and could be frequent in COVID-19 [11]. However, these antibodies are often non-pathogenic in severe infections, and their persistence should therefore be checked after COVID-19 recovery.

Finally, monitoring the hemostasis of COVID-19 patients is essential for the diagnose of DIC, which complicates severe forms [2], and should be suspected with classic manifestations including thrombocytopenia, prolongation of APTT and PT, decrease in fibrinogen levels, elevation of D-dimers, and the presence of fibrin monomers.

Conclusion

COVID-19 is a disease with high thrombotic risk, and heparin therapy with doses of LMWH or UFH adjusted to the level of risk are required in all hospitalized patients, especially in obese and critically ill patients. Regular biological monitoring is essential to optimize anticoagulant management and treatment, and it is important to strengthen collaboration and communication between the ICUs and the hematology laboratory.

Acknowledgements

The authors gratefully thank all following members of the GHFP and the GHFT for their help in defining these proposals.

Members of the “Groupe d’intérêt en hémostase périopératoire” (GHFP):
P. Albaladejo (Anesthesia and Critical Care, Grenoble France), N. Blais (Hematology-Hemostasis, Montréal, Canada), F. Bonhomme (Anesthesia and Critical Care, Geneva, Switzerland), A. Borel-Derlon (Hematology-Hemostasis, Caen, France), A. Cohen (Cardiology, Paris, France), J.P. Collet (Cardiology, Paris, France), E. de Maistre (Hematology-Hemostasis, Dijon, France), P. Fontana (Hematology-Hemostasis, Geneva, Switzerland), D. Garrigue Huet (Anesthesia and Critical Care, Lille, France), A. Godier (Anesthesia and Critical Care, Paris, France), Y. Gruel (Hematology-Hemostasis, Tours, France), A. Godon (Anesthesia and Critical Care, Grenoble, France), B. Ickx (Anesthesia and Critical Care, Brussels, Belgium), S. Laporte (Clinical Pharmacology, Saint-Etienne, France), D. Lasne (Hematology-Hemostasis, Paris, France), J. Llau (Anesthesia and Critical Care, Valencia, Spain), G. Le Gal (Vascular Medicine, Ottawa, Canada), T. Lecompte (Hematology-Hemostasis, Geneva, Switzerland), S. Lessire (Anesthesia and Critical Care, Namur, Belgium), J.H. Levy (Anesthesia and Critical Care, Durham, USA), D. Longrois (Anesthesia and Critical Care, Paris, France), S. Madj-Lebara (Anesthesia and Critical Care, Beyrouth, Lebanon), A. Mansour (Anesthesia and Critical Care, Rennes, France), M. Mazighi (Neurology, Paris, France), P. Mismetti (Clinical Pharmacology, Saint-Etienne), P.E. Morange (Hematology-Hemostasis, Marseille, France), S. Motte (Vascular Medicine, Brussels, Belgium), F. Mullier (Hematology-Hemostasis, Namur, Belgium), N. Nathan (Anesthesia and Critical Care, Lille, France), P. Nguyen (Hematology-Hemostasis, Reims, France), G. Perrot (Vascular Medicine, Grenoble, France), N. Rosencher (Anesthesia and Critical Care, Paris, France), S. Rouillet (Anesthesia and Critical Care, Bordeaux, France), P.M. Roy (Emergency Medicine, Angers, France), S. Schlumberger (Anesthesia and Critical Care, Suresnes, France), P. Sié (Hematology-Hemostasis, Toulouse, France), A. Steib (Anesthesia and Critical Care, Strasbourg, France), S. Testa (Hematology, Cremona, Italy), A. Vincentelli (Cardiac Surgery, Lille, France), and P. Zufferey (Anesthesia and Critical Care, Saint-Etienne, France).

Members of the “Groupe Français d’études sur l’Hémostase et la Thrombose” (GHFT):
A. Borel-Derlon (Hematology-Hemostasis, Caen), E Boissier (Hematology-Hemostasis, Nantes), B Delmont (Hematology-Hemostasis, Paris), E. de Maistre (Hematology-Hemostasis, Dijon), Y. Gruel (Hematology-Hemostasis, Tours, France), C. James (Hematology, Bordeaux), D. Lasne (Hematology-Hemostasis, Paris), T. Lecompte (Hematology-Hemostasis, Genève, Suisse), P.E. Morange (Hematology-Hemostasis, Marseille), P. Nguyen (Hematology-Hemostasis, Reims, France), P. Sié (Hematology-Hemostasis, Toulouse), V. Sigueret (Hematology-Hemostasis, Paris), and S. Susen (Hematology-Hemostasis, Lille, France).

Authors’ contributions

SS and YG wrote the first draft of the manuscript from March 15th to April 1st, which was then extensively reviewed and amended by all authors,
according to the comments of the GIHP and GFHT members listed in the acknowledgements. All author(s) read and approved the final manuscript submitted on April 21.

**Funding**
None

**Availability of data and materials**
Not applicable

**Ethics approval and consent to participate**
Not applicable

**Consent for publication**
Not applicable

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Department of Hematology and Transfusion, Lille University Hospital, Lille, France. 2Department of Hemostasis and Transfusion, CHU Lille, Lille, France. 3Department of Anesthesiology and Critical Care, Strasbourg University Hospital, Strasbourg, France. 4Department of Anesthesiology and Critical Care, Grenoble Alpes University Hospital, La Tronche, France. 5Department of Anesthesiology and Critical Care Medicine, Rennes University Hospital, Rennes, France. 6Department of Hematology Laboratory, Reims University Hospital, Reims, France. 7Department of Anesthesia and Intensive Care, HEGP-AP-HF, Paris, France. 8AO Istituti Ospitalieri, Cremona, Italy. 9Duke University Hospital, Durham, NC, USA. 10Department of Hematology-Hemostasis, Tours University Hospital, CHRU Tours, Tours, France. 11Anesthesia and Critical Care, Grenoble, France. 12Hematology-Hemostasis, Montréal, Canada. 13Anesthesia and Critical Care, Geneva, Switzerland. 14Hematology-Hemostasis, Caen, France. 15Cardiology, Paris, France. 16Hematology-Hemostasis, Dijon, France. 17Hematology-Hemostasis, Geneva, Switzerland. 18Anesthesia and Critical Care, Lille, France. 19Anesthesia and Critical Care, Paris, France. 20Hematology-Hemostasis, Tours, France. 21Anesthesia and Critical Care, Brussels, Belgium. 22Clinical Pharmacology, Saint-Etienne, France. 23Hematology-Hemostasis, Paris, France. 24Anesthesia and Critical Care, Valencia, Spain. 25Vascular Medicine, Ottawa, Canada. 26Anesthesia and Critical Care, Namur, Belgium. 27Anesthesia and Critical Care, Durham, USA. 28Anesthesia and Critical Care, Beyrouth, Lebanon. 29Anesthesia and Critical Care, Rennes, France. 30Neurology, Paris, France. 31Hematology-Hemostasis, Marseille, France. 32Vascular Medicine, Brussels, Belgium. 33Hematology-Hemostasis, Namur, Belgium. 34Anesthesia and Critical Care, Limoges, France. 35Hematology-Hemostasis, Reims, France. 36Vascular Medicine, Grenoble, France. 37Anesthesia and Critical Care, Bordeaux, France. 38Emergency Medicine, Angers, France. 39Anesthesia and Critical Care, Suresnes, France. 40Hematology-Hemostasis, Toulouse, France. 41Anesthesia and Critical Care, Strasbourg, France. 42Hematology-Hemostasis, Lille, France. 43Hematology, Cremona, Italy. 44Cardiac Surgery, Lille, France. 45Anesthesia and Critical Care, Saint-Etienne, France. 46Hematology-Hemostasis, Nantes, France. 47Hematology, Bordeaux, France. 48Hematology-Hemostasis, Genève, Suisse.

Received: 24 April 2020 Accepted: 18 May 2020 Published online: 19 June 2020

**References**
1. Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western Medicine for the management of 2019 novel coronavirus disease. Am J Chinese Med. 2020;48(3):737–62.
2. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.
3. Averitt M, Yin E, Klaflf L, Lokhandwala S, Redo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020. https://doi.org/10.1001/jama.2020.4326.
4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabini L, Castelli A, Cereda D, Coluccello A, Foni G, Fumagalli R, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.5394.
5. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.4683.
6. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020. https://doi.org/10.1016/j.ijid.2020.03.017.
7. Huang R, Zhu L, Xue L, Liu Y, Yan X, Wang J, et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. PLoS Negl Trop Dis. 2020;14(5):e0008280.
8. Simonnet A, Chetboun M, Poissy J, Ravery V, Noutelle J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring, Md). 2020. doi https://doi.org/10.1002/oby.22831.
9. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe coronavirus pneumonia. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14830.
10. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paasen J, Stals MAM, Huisman MW, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. https://doi.org/10.1016/j.thromres.2020.04.041.
11. Helms J, Tacquard C, Severac F, Leonard-Lorant J, Omana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fogat Gandet F, et al. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047430.
12. Poissy J, Goutay J, Caplan M, Parmentier E, Dubucur T, Lassalle F, Jeannine E, Rausch A, Labreuche J, Susen S. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047430.
13. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, AI, Charles DS, Baeleakian AA, Klein RC, Le H, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):S2S–S225.
14. Schunemann HJ, Cushman M, Béparer AE, Kahn SR, Beyer-Westendorf J, Spencer FA, Rezende SM, Zaki NA, Bauer KA, Dentali F, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. J Thromb Haemost. 2018;16(2):2198–225.
15. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18(5): 1020–2.
16. Rocca B, Fox KAA, Ajan RA, Andreotti F, Baignet C, Collet JP, Grove EL, Halvorsen S, Huber K, Morais J, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672–1686.
17. Cook D, Douketis J, Crotwell MA, Anderson DR. The diagnosis of deep venous thrombosis and pulmonary embolism in medical-surgical intensive care unit patients: J Crit Care. 2005;20(4):314–9.
18. Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA, Rondina MT. VTE incidence and risk factors in patients with severe sepsis and septic shock. Chest. 2015;148(5):1224–30.
19. Lim W, Meade M, Laufer Z, Zanyarchani R, Mehta S, Lamontagne F, Dodek P, McIntyre L, Hall R, Heels-Ansdell D, et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med. 2015;43(2):401–10.
20. Obi AT, Tignaneli CJ, Jacobs BN, Arya S, Park PK, Wakefield TW, Henke PK, Napolitano LM. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg. 2019;70(3):317–24.
21. Fan H, Zhang L, Huang B, et al. Retrospective analysis of clinical features in 101 death cases with COVID-19. Submitted. doi 10.1101/2020030920033068. 2020.
22. Zhang B, Zhou X, Qiu J, et al. Clinical characteristics of 82 death cases with COVID-19. Submitted. doi 10.1101/2020022620028191. 2020.
23. Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257–91.

24. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020. https://doi.org/10.1515/ccdm-2020-0188.

25. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV-2 and non-SARS-CoV-2. J Thromb Thrombolysis. 2020. https://doi.org/10.1007/s11239-020-02105-8.

26. Cattaneo M, Bertinato EM, Biocchi S, Brito C, Malavolta D, Manzoni M, Muscarella G, Orlandi M. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020. https://doi.org/10.1055/s-0040-1712097.

27. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020. https://doi.org/10.1182/blood.2020006000.

28. Egan G, Ensom MH. Measuring anti-factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hospit Pharm. 2015;68(1):33–47.

29. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S–43S.

30. Cuker A, Arepally GM, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, TEW, et al. American Society of Hematology 2018. Guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–92.

31. Allingstrup M, Wetterles J, Ravn FB, Moller AM, Alfshari A. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2016;2:Cd005370.

32. Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost. 2006;95(5):850–6.

33. Chlebowski MM, Baltagi S, Carlson M, Levy JH, Spinella PC. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Critical care (London). 2020;24(1):19.

34. Gruel Y, De Maistre E, Pouplard C, Mullier F, Susen S, Rouillet S, Blais N, Le Gal G, Vincentelli A, Lasne D, et al. Diagnosis and management of heparin-induced thrombocytopenia. Anaesthesia Crit Pain Med. 2020. https://doi.org/10.1016/j.acpcm.2020.03.012.

35. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.